亚洲和非洲部分国家狂犬病暴露后预防可及性、采购与分发概况(2017—2018年)
研究向亚洲和非洲25个中低收入国家发放标准化评估工具,收集狂犬病暴露后预防(PEP)的采购、预测、分发与监测信息。23国应答显示,仅9国公共部门免费且持续供应疫苗,10国患者需自付且单剂费用为6.60至20美元,主要障碍为政府及患者成本高。
要点
- 23国中仅9国公共部门免费且持续供应狂犬病疫苗。
- 10国患者需自付疫苗费用,单剂6.60至20美元。
- 仅5国完全采用皮内注射以减少疫苗用量。
核心结论
- 评估国家公共部门均有狂犬病疫苗供应,但政府与患者的高成本构成可及性障碍。
- 应鼓励采用皮内注射,以相同疫苗瓶数为更多人提供接种。
- 应鼓励标准化监测与报告疫苗使用,以改善PEP需求数据。
研究设计与样本
- 向亚洲和非洲25个中低收入国家便利抽样发放标准化电子评估工具。
- 信息来自国家狂犬病联络点、WHO国家办事处联络点及其他采购物流人员。
- 数据收集时间为2017年1月至2018年5月,评估聚焦疫苗因RIG多国有限或不可得。
主要发现
- 共23国应答:亚洲11国、非洲12国。
- 9/23(39%)国家公共部门免费提供疫苗且持续可得。
- 10(43%)国家公共部门全部或部分患者需付费,单剂6.60至20美元。
- 4(17%)国家疫苗免费但常不可得,患者需自行购买。
- 5国完全使用皮内注射;11/22(50%)有独立于常规儿童疫苗的标准化PEP分发系统;9/22(41%)有定期报告。
关键数值与推荐
- 单剂疫苗患者自付费用范围为6.60至20美元(10国)。
- 患者疫苗费用高的主因是中央层面缺乏补贴资金。
- 多数国家采用肌内注射,仅5国完全采用皮内注射。
- 11/22(50%)国家有标准化PEP分发系统,9/22(41%)有定期报告。
临床怎么用
- 在PEP可及性评估中应同时关注政府采购成本与患者自付费用。
- 可优先考虑皮内注射以在相同疫苗瓶数下扩大覆盖。
- 应建立标准化疫苗使用监测与报告以支撑PEP需求预测。
局限性
- 采用便利抽样,非随机代表性样本。
- 评估因RIG多国有限或不可得而聚焦疫苗。
- 信息来自关键知情人报告,可能存在报告偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rabies is a neglected zoonotic disease with a global burden of approximately 59,000 human deaths a year. Once clinical symptoms appear, rabies is almost invariably fatal; however, with timely and appropriate post-exposure prophylaxis (PEP) consisting of wound washing, vaccine, and in some cases rabies immunoglobulin (RIG), the disease is almost entirely preventable. Access to PEP is limited in many countries, and when available, is often very expensive. METHODS: We distributed a standardized assessment tool electronically to a convenience sample of 25 low- and middle-income countries in Asia and Africa to collect information on rabies PEP procurement, forecasting, distribution, monitoring and reporting. Information was collected from national rabies focal points, focal points at the World Health Organization (WHO) country offices, and others involved in procurement, logistics and distribution of PEP. Because RIG was limited in availability or unavailable in many countries, the assessment focused on vaccine. Data were collected between January 2017 and May 2018. RESULTS: We received responses from key informants in 23 countries: 11 countries in Asia and 12 countries in Africa. In 9 of 23 (39%) countries, rabies vaccine was provided for free in the public sector and was consistently available. In 10 (43%) countries, all or some patients were required to pay for the vaccine in the public sector, with the cost of a single dose ranging from US$ 6.60 to US$ 20/dose. The primary reason for the high cost of the vaccine for patients was a lack of funding at the central level to subsidize vaccine costs. In the remaining 4 (17%) countries, vaccine was provided for free but was often unavailable so patients were required to purchase it instead. The majority of countries used the intramuscular route for vaccine administration and only 5 countries exclusively used the dose-sparing intradermal (ID) route. Half (11/22; 50%) of all countries assessed had a standardized distribution system for PEP, separate from the systems used for routine childhood vaccines, and almost half used separate storage facilities at both central and health facility levels. Approximately half (9/22; 41%) of all countries assessed reported having regular weekly, monthly or quarterly reporting on rabies vaccination. CONCLUSIONS: While all countries in our assessment had rabies vaccines available in the public sector to some extent, barriers to access include the high cost of the vaccine to the government as well as to patients. Countries should be encouraged to use ID administration as this would provide access to rabies vaccine for many more people with the same number of vaccine vials. In addition, standardized monitoring and reporting of vaccine utilization should be encouraged, in order to improve data on PEP needs.
引用
- Sreenivasan N, Li A, Shiferaw M, et al. Overview of rabies post-exposure prophylaxis access, procurement and distribution in selected countries in Asia and Africa, 2017-2018. Vaccine. 2019. PMID: 31471150. doi:10.1016/j.vaccine.2019.04.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。